Literature DB >> 19000021

Impaired viral entry cannot explain reduced CD4+ T cell susceptibility to HIV type 1 in certain highly exposed individuals.

Emily C Speelmon1, Devon Livingston-Rosanoff, Anthony L Desbien, Jean Lee, W David Wick, Florian Hladik, M Juliana McElrath.   

Abstract

Rare individuals report repeated unprotected HIV-1 sexual exposures, yet remain seronegative for years. We investigated the possibility that reduced in vitro CD4(+) T cell susceptibility to HIV-1 infection protects such highly exposed seronegative (ES) individuals. Susceptibility to three R5-tropic HIV-1 isolates, regardless of inoculating dose, was remarkably similar between 81 ES and 33 low-risk controls. In 94% (99/105) of donors, we observed a 1.36 log-unit range in HIV-1(JR-CSF) production, with similar results for HIV-1(1192). The median frequency of intracellular Gag(+) T cells after single-round infection was similar in ES (5.2%) and controls (7.2%), p = 0.456. However, in repeated testing, CD4(+) T cells from two controls (6.1%) and four ES (4.9%) exhibited a 10- to 2500-fold reduction in HIV-1 production and required 5- to 12-fold greater HIV-1(1192) and HIV-1(JR-CSF) inocula to establish infection (TCID(50)). Reduced viral entry cannot explain the low producer phenotype; no differences in CCR5 receptor density or beta-chemokine production were observed. In conclusion, we have identified a remarkably narrow range of HIV-1 susceptibility in seronegative donors regardless of risk activity, which can be applied as a benchmark to assess vaccine-induced antiviral effector activities. However, CD4(+) T cells from a subset of individuals demonstrated reduced HIV-1 susceptibility unexplained by impaired entry, lending support to the possibility that cellular restriction of HIV-1 may account for continued seronegativity in some of those having repeated sexual exposure. Identifying the host-virus interactions responsible for diminished in vitro susceptibility may contribute to the development of novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19000021      PMCID: PMC2764523          DOI: 10.1089/aid.2007.0256

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  76 in total

1.  Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding.

Authors:  J E Garrus; U K von Schwedler; O W Pornillos; S G Morham; K H Zavitz; H E Wang; D A Wettstein; K M Stray; M Côté; R L Rich; D G Myszka; W I Sundquist
Journal:  Cell       Date:  2001-10-05       Impact factor: 41.582

2.  Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.

Authors:  U O'Doherty; W J Swiggard; M H Malim
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Analysis of cellular factors influencing the replication of human immunodeficiency virus type I in human macrophages derived from blood of different healthy donors.

Authors:  V Eisert; M Kreutz; K Becker; C Königs; U Alex; H Rübsamen-Waigmann; R Andreesen; H von Briesen
Journal:  Virology       Date:  2001-07-20       Impact factor: 3.616

4.  HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi.

Authors:  R Kaul; F A Plummer; J Kimani; T Dong; P Kiama; T Rostron; E Njagi; K S MacDonald; J J Bwayo; A J McMichael; S L Rowland-Jones
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

5.  Early HIV infection in vivo: branching-process model for studying timing of immune responses and drug therapy.

Authors:  D Wick; S G Self
Journal:  Math Biosci       Date:  2000-06       Impact factor: 2.144

6.  Immune defence against HIV-1 infection in HIV-1-exposed seronegative persons.

Authors:  S C Schmechel; N Russell; F Hladik; J Lang; A Wilson; R Ha; A Desbien; M J McElrath
Journal:  Immunol Lett       Date:  2001-11-01       Impact factor: 3.685

7.  CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects.

Authors:  R Kaul; T Dong; F A Plummer; J Kimani; T Rostron; P Kiama; E Njagi; E Irungu; B Farah; J Oyugi; R Chakraborty; K S MacDonald; J J Bwayo; A McMichael; S L Rowland-Jones
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

8.  Intrinsic susceptibility of rhesus macaque peripheral CD4(+) T cells to simian immunodeficiency virus in vitro is predictive of in vivo viral replication.

Authors:  S Goldstein; C R Brown; H Dehghani; J D Lifson; V M Hirsch
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  No difference in in vitro susceptibility to HIV type 1 between high-risk HIV-negative Ethiopian commercial sex workers and low-risk control subjects.

Authors:  T Messele; T F Rinke de Wit; M Brouwer; M Aklilu; T Birru; A L Fontanet; H Schuitemaker; D Hamann
Journal:  AIDS Res Hum Retroviruses       Date:  2001-03-20       Impact factor: 2.205

10.  Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals.

Authors:  Tuofu Zhu; Lawrence Corey; Yon Hwangbo; Jean M Lee; Gerald H Learn; James I Mullins; M Juliana McElrath
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more
  1 in total

1.  An excess of rare genetic variation in ABCE1 among Yorubans and African-American individuals with HIV-1.

Authors:  D C Crawford; N Zheng; E C Speelmon; I Stanaway; M J Rieder; D A Nickerson; M J McElrath; J Lingappa
Journal:  Genes Immun       Date:  2009-08-06       Impact factor: 2.676

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.